SPS
URGN icon

Susquehanna Portfolio Strategies’s UroGen Pharma URGN Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$714K Hold
19,404
– – 0.01% 617
2026
Q1 		$349K Sell
19,404
-7,976
-29% -$160K 0.01% 822
2025
Q4 		$641K Buy
+27,380
New +$594K 0.01% 727

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Susquehanna Portfolio Strategies's URGN Position: Q2 2026 in Review

Susquehanna Portfolio Strategies held its UroGen Pharma (URGN) position steady in Q2 2026 at 19,404 shares worth $714K. The position accounts for 0.01% of the portfolio, ranked #617.

Susquehanna Portfolio Strategies first reported a position in URGN in Q4 2025 and has held it in 3 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Susquehanna Portfolio Strategies held 19,404 shares of UroGen Pharma worth $714K as of Q2 2026.
  • Susquehanna Portfolio Strategies left its UroGen Pharma share count unchanged in Q2 2026.
  • UroGen Pharma made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #617 holding.
  • Susquehanna Portfolio Strategies first reported a position in UroGen Pharma in Q4 2025 and has held it in 3 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.